{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:47Z","timestamp":1786982747949,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40256-025-00774-5","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:24:49Z","timestamp":1763141089000},"page":"257-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An Updated Review of Novel Triglyceride-Lowering Therapies in Adults with Familial Chylomicronemia Syndrome"],"prefix":"10.1007","volume":"26","author":[{"given":"Sharmane","family":"Joubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Ninan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9965-0956","authenticated-orcid":false,"given":"Natalie","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1570-6693","authenticated-orcid":false,"given":"Shantera","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-4875","authenticated-orcid":false,"given":"Joshua","family":"Wollen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5655-5318","authenticated-orcid":false,"given":"Elisabeth M.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"4","key":"774_CR1","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/j.jacl.2025.03.013","volume":"17","author":"F Javed","year":"2023","unstructured":"Javed F. A rare dyslipidemia: review of diagnosis and therapeutics in management of familial chylomicronemia syndrome (FCS). J Clin Lipidol. 2023;17(4):e53\u20134. https:\/\/doi.org\/10.1016\/j.jacl.2025.03.013.","journal-title":"J Clin Lipidol"},{"key":"774_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.119114","volume":"403","author":"EA Brinton","year":"2025","unstructured":"Brinton EA, Eckel RH, Gaudet D, Ballantyne CM, Baker BF, Ginsberg HN, et al. Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA. Atherosclerosis. 2025;403:119114. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119114.","journal-title":"Atherosclerosis"},{"issue":"19","key":"774_CR3","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1177\/2047487319888054","volume":"27","author":"VA Pallazola","year":"2020","unstructured":"Pallazola VA, Sajja A, Derenbecker R, Ogunmoroti O, Park J, Sathiyakumar V, et al. Prevalence of familial chylomicronemia syndrome in a quaternary care center. Eur J Prev Cardiol. 2020;27(19):2276\u20138. https:\/\/doi.org\/10.1177\/2047487319888054.","journal-title":"Eur J Prev Cardiol"},{"issue":"15","key":"774_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154311","volume":"11","author":"\u00c1 N\u00e9meth","year":"2022","unstructured":"N\u00e9meth \u00c1, Harangi M, Dar\u00f3czy B, Juh\u00e1sz L, Paragh G, F\u00fcl\u00f6p P. Identifying patients with familial chylomicronemia syndrome using FCS score-based data mining methods. J Clin Med. 2022;11(15):4311. https:\/\/doi.org\/10.3390\/jcm11154311.","journal-title":"J Clin Med"},{"issue":"4","key":"774_CR5","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1210\/clinem\/dgae613","volume":"110","author":"CM Spagnuolo","year":"2025","unstructured":"Spagnuolo CM, Wang J, McIntyre AD, Kennedy BA, Hegele RA. Comparison of patients with familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome. J Clin Endocrinol Metab. 2025;110(4):1158\u201365. https:\/\/doi.org\/10.1210\/clinem\/dgae613.","journal-title":"J Clin Endocrinol Metab"},{"key":"774_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","volume":"275","author":"P Moulin","year":"2018","unstructured":"Moulin P, Dufour R, Averna M, Arca M, Cefal\u00f9 AB, Noto D, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \u201cFCS score.\u201d Atherosclerosis. 2018;275:265\u201372. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.814.","journal-title":"Atherosclerosis"},{"issue":"4","key":"774_CR7","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf025","volume":"9","author":"M Larouche","year":"2025","unstructured":"Larouche M, Banerjee P, Brisson D, Pordy R, Gaudet D. Treatment with evinacumab links a new pathogenic variant in the LPL gene to persistent chylomicronemia. J Endocr Soc. 2025;9(4):bvaf025. https:\/\/doi.org\/10.1210\/jendso\/bvaf025.","journal-title":"J Endocr Soc"},{"issue":"3","key":"774_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","volume":"29","author":"RS Rosenson","year":"2023","unstructured":"Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29(3):729\u201337. https:\/\/doi.org\/10.1038\/s41591-023-02222-w.","journal-title":"Nat Med"},{"issue":"4","key":"774_CR9","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","volume":"12","author":"L Williams","year":"2018","unstructured":"Williams L, Rhodes KS, Karmally W, Welstead LA, Alexander L, Sutton L. Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span. J Clin Lipidol. 2018;12(4):908\u201319. https:\/\/doi.org\/10.1016\/j.jacl.2018.04.010.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"774_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11883-023-01080-8","volume":"25","author":"A Giammanco","year":"2023","unstructured":"Giammanco A, Spina R, Cefal\u00f9 AB, Averna M. APOC-III: a gatekeeper in controlling triglyceride metabolism. Curr Atheroscler Rep. 2023;25(3):67. https:\/\/doi.org\/10.1007\/s11883-023-01080-8.","journal-title":"Curr Atheroscler Rep"},{"issue":"23","key":"774_CR11","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200\u20136. https:\/\/doi.org\/10.1056\/NEJMoa1400284.","journal-title":"N Engl J Med"},{"key":"774_CR12","unstructured":"FDA approves drug to reduce triglycerides in adult patients with familial chylomicronemia syndrome. U.S. Food & Drug Administration. Published December 19, 2024. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-reduce-triglycerides-adult-patients-familial-chylomicronemia-syndrome#:~:text=The%20U.S.%20Food%20and%20Drug,currently%20used%20to%20treat%20FCS. Accessed 18 July 2025."},{"issue":"1","key":"774_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"774_CR14","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.2147\/DDDT.S224771","volume":"14","author":"O Esan","year":"2020","unstructured":"Esan O, Wierzbicki AS. Volanesorsen in the treatment of familial chylomicronemia syndrome or hypertriglyceridaemia: design, development and place in therapy. Drug Des Devel Ther. 2020;14:2623\u201336. https:\/\/doi.org\/10.2147\/DDDT.S224771.","journal-title":"Drug Des Devel Ther"},{"key":"774_CR15","unstructured":"Tryngolza [package insert]. Carlsbad, CA: Ionis Pharmaceuticals, Inc.; 2024. https:\/\/ionis.com\/sites\/default\/files\/2025-03\/TRYNGOLZA-olezarsen-FPI.pdf. Accessed July 18, 2025."},{"key":"774_CR16","unstructured":"Waylivra [package insert]. Dundalk, Ireland: Almac Pharma Services Ireland Ltd.; 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/waylivra-epar-product-information_en.pdf. Accessed July 18, 2025."},{"issue":"2","key":"774_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa2409368","volume":"392","author":"GF Watts","year":"2025","unstructured":"Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med. 2025;392(2):127\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2409368.","journal-title":"N Engl J Med"},{"issue":"12","key":"774_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200325","volume":"2","author":"D Gaudet","year":"2023","unstructured":"Gaudet D, Clifton P, Sullivan D, Baker J, Schwabe C, Thackwray S, et al. RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia. NEJM Evid. 2023;2(12):EVIDoa2200325. https:\/\/doi.org\/10.1056\/EVIDoa2200325.","journal-title":"NEJM Evid"},{"key":"774_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.70055","author":"J Ousey","year":"2025","unstructured":"Ousey J, Jomphe C, Ta A, Gosselin NH, Shi J. Population pharmacokinetic modeling of subcutaneous plozasiran in healthy volunteers and patients with familial chylomicronemia syndrome, severe hypertriglyceridemia, and mixed hyperlipidemia. J Clin Pharmacol. 2025. https:\/\/doi.org\/10.1002\/jcph.70055.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"774_CR20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"8","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;8(6):531\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1715944.","journal-title":"N Engl J Med"},{"issue":"3","key":"774_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacl.2024.12.018","volume":"19","author":"S Tsimikas","year":"2025","unstructured":"Tsimikas S, Ginsberg HN, Alexander VJ, Karwatowska-Prokopczuk E, Dibble A, Li L, et al. Differential effects of volanesorsen on apoC-III, triglycerides, and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or nongenetic criteria. J Clin Lipidol. 2025;19(3):422\u201331. https:\/\/doi.org\/10.1016\/j.jacl.2024.12.018.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"774_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","volume":"9","author":"I Gouni-Berthold","year":"2021","unstructured":"Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(5):264\u201375. https:\/\/doi.org\/10.1016\/S2213-8587(21)00046-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"19","key":"774_CR23","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","volume":"390","author":"ESG Stroes","year":"2024","unstructured":"Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390(19):1781\u201392. https:\/\/doi.org\/10.1056\/NEJMoa2400201.","journal-title":"N Engl J Med"},{"key":"774_CR24","unstructured":"Akcea and Ionis announce approval of WAYLIVRA\u00ae (volanesorsen) in the European Union | Ionis Pharmaceuticals, Inc. [Internet]. [cited 2025 June 7]. Available from: https:\/\/ir.ionis.com\/news-releases\/news-release-details\/akcea-and-ionis-announce-approval-waylivrar-volanesorsen."},{"key":"774_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf190","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, Tokg\u00f6zo\u011flu L, Badimon L, Baigent C, et al. Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","journal-title":"Eur Heart J"},{"key":"774_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2023.05.008","volume":"375","author":"A Jones","year":"2023","unstructured":"Jones A, Peers K, Wierzbicki AS, Ramachandran R, Mansfield M, Dawson C, et al. Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK early access to medicines scheme (EAMS). Atherosclerosis. 2023;375:67\u201374. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.05.008.","journal-title":"Atherosclerosis"},{"issue":"4","key":"774_CR27","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jacl.2025.04.203","volume":"19","author":"A Rom\u00e1n-Gonz\u00e1lez","year":"2025","unstructured":"Rom\u00e1n-Gonz\u00e1lez A, Castellanos A, Perdomo D, Col\u00f3n C, Vargas JJ, Mendivil CO, et al. Real life evidence of volanesorsen for familial chylomicronemia syndrome in Colombia. J Clin Lipidol. 2025;19(4):1101\u20138. https:\/\/doi.org\/10.1016\/j.jacl.2025.04.203.","journal-title":"J Clin Lipidol"},{"key":"774_CR28","unstructured":"Olezarsen. In: Lexi-Drugs. UpToDate Inc. UpToDate Inc. Updated July 7, 2025. http:\/\/online.lexi.com. Accessed 18 July 2025."},{"key":"774_CR29","doi-asserted-by":"publisher","first-page":"156187","DOI":"10.1016\/j.metabol.2025.156187","volume":"167","author":"M de Moura de Souza","year":"2025","unstructured":"de Moura de Souza M, Mendes BX, Defante MLR, de Athayde de Hollanda Morais BA, Martins OC, Priz\u00e3o VM, et al. Apolipoprotein C-III inhibitors for the treatment of hypertriglyceridemia: a meta-analysis of randomized controlled trials. Metabolism. 2025;167:156187. https:\/\/doi.org\/10.1016\/j.metabol.2025.156187.","journal-title":"Metabolism"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00774-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00774-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00774-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:36:45Z","timestamp":1776857805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00774-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["774"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00774-5","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Elisabeth M. Wang reports a relationship with Pharmacy Times Office of Continuing Professional Education LLC that includes: speaking and lecture fees. Sharmane Joubert, Jeremy Ninan, Natalie Rosario, Shantera Davis, and Joshua Wollen declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Sharmane Joubert: Investigation, Writing\u2014original draft, Writing\u2014review and editing.\u00a0Jeremy Ninan: Investigation, Writing\u2014original draft, Writing\u2014review & editing.\u00a0Natalie Rosario: Writing\u2014review & editing.\u00a0Shantera Davis: Writing\u2014review & editing.\u00a0Joshua Wollen: Writing\u2014review & editing.\u00a0Elisabeth Wang: Investigation, Writing\u2014review and editing, Writing\u2014original draft, Visualization, Supervision, Conceptualization.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Data sharing not applicable to this article as no datasets were generated for the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}